赛诺菲制造和供应执行副总裁Brendan O ‘Callaghan在一份声明中表示，这个模块化工厂使公司能够在公共卫生挑战发生时紧急应对。赛诺菲今年早些时候在法国完成了另一个这样的模块化设施。French pharmaceutical giant Sanofi announced on Wednesday that it will build a new factory in Singapore to produce vaccines and other pharmaceuticals to enhance preparedness for emergencies, including potential epidemics.
According to a statement, the factory named Modulus is built in Singapore's Biopolis Biomedical Sciences Park with an investment of 0.8 billion Singapore dollars (nearly 0.6 billion US dollars). It can simultaneously produce up to four vaccines or biopharmaceuticals and is scheduled to be fully operational by mid-2026, creating 200 technical jobs in Singapore.
The company stated that Modulus can be reconfigured in a matter of days to switch between technology platforms, a process that typically takes months or years. It can accommodate the equivalent of 34 standardized production modules.
Sanofi's Manufacturing and Supply Operations Vice President Brendan O'Callaghan stated in a declaration that this modular factory enables the company to respond quickly to public health challenges when they occur. Sanofi earlier this year completed another similar modular facility in France.
